View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
November 30, 2016

MilliporeSigma collaborates with Evotec for screening of customised CRISPR and shRNA libraries

MilliporeSigma has entered into a set of agreements with Evotec to expedite screening of customised CRISPR and shRNA libraries for a rapid and efficient exploration of disease pathways.

MilliporeSigma has entered into a set of agreements with Evotec to expedite screening of customised CRISPR and shRNA libraries for a rapid and efficient exploration of disease pathways.

Under the agreements, Evotec will provide screening services for MilliporeSigma's collection of genetic reagents such as CRISPR and shRNA libraries.

MilliporeSigma applied solutions strategic marketing and innovation head said: "Drug discovery starts with the identification of new targets, a process that can be time and labor intensive.

"Our collaboration with Evotec accelerates the discovery workflow, enabling customers to more rapidly and efficiently explore disease pathways and find new targets."

The collaboration is expected to enable selection of customised set of CRISPR and shRNA libraries, and use Evotec's capabilities in phenotypic screening within primary and induced pluripotent stem cells and in vivo disease models.

"Deploying MilliporeSigma's assay-ready reagents on our cellular screening platforms and in-vivo models creates powerful drug discovery capabilities and more value to our customers through such a comprehensive solution."

The custom-engineered cell lines developed by MilliporeSigma's Cell Design Studio will further facilitate the target identification workflow as it will be used by Evotec to customise screening assays.

Evotec chief operating officer Dr Mario Polywka said: "This agreement with MilliporeSigma further strengthens our offering in the area of target identification and validation.

"Deploying MilliporeSigma's assay-ready reagents on our cellular screening platforms and in-vivo models creates powerful drug discovery capabilities and more value to our customers through such a comprehensive solution."


Image: A hand holding a pen infront of a strand of DNA. Photo: courtesy of MilliporeSigma.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU